| The following article features coverage from the National Kidney Foundation’s 2019 Spring Clinical Meetings. Click here to read more of Renal & Urology News’ conference coverage. |
Patients on hemodialysis (HD) who stay on the phosphate binder sucroferric oxyhydroxide (SO) for 2 years may have lower hospital admissions rates than those who switch from SO to another phosphate binder for 2 years, according to study data presented at the National Kidney Foundation’s 2019 Spring Clinical Meetings in Boston.
In a retrospective study, a team led by Daniel W. Coyne, MD, of Washington University School of Medicine in St. Louis analyzed data from HD patients with 2 years of phosphate binder prescriptions and divided them into patients prescribed SO, an iron-based phosphate binder, as part of routine care (mSO, 222 patients) and those who discontinued SO (dSO, 596 patients) within 90 days and switched to 2 years of treatment with another binder.
Patients in the mSO group (who received SO treatment for 2 years) experienced 574 hospitalizations in 444 person-years, whereas those in the dSO group had 1860 hospitalizations in 1186 person-years. Compared with the dSO group, the mSO group had 35.6 fewer hospital admissions per 100 patient-years, for a potential annual cost savings of $566,295 per 100 patients, Dr Coyne and his colleagues reported in a poster presentation.
Continue Reading
For the study, the investigators used data from patients in the Fresenius Kidney Care database. They based calculation of cost savings on data from the 2018 US Renal Data System annual report showing that the total inpatient expenditure per HD patient was $27,654 and the hospitalization rate per year was 1.73846. This works out an average cost per hospitalization of $15,907.
Read more of Renal & Urology News’ coverage of NKF’s 2019 Spring Clinical Meetings by visiting the conference page.
Reference
Rosen MM, Ficociello LH, Parameswaran V, et al. Hospital admission rates among hemodialysis patients who switch to sucroferric oxyhydroxide (SO) compared to patients who discontinue SO and receive other phosphate binders. Poster presented at the National Kidney Foundation’s 2019 Spring Clinical Meetings in Boston, May 8-12. Poster 220.
